Changes in Beneficial Ownership · 4
Quest Diagnostics Inc.
DGXNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1788208632.xml
Filing details
- Report period
- 2026-08-28
- Issuer
- QUEST DIAGNOSTICS INC
- Issuer CIK
- 0001022079
- Trading symbol
- DGX
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- PREVOZNIK MICHAEL E
- Reporting owner CIK
- 0001222679
- Relationship
- Officer
- Officer title
- SVP & General Counsel
- Address
- 500 PLAZA DRIVE, SECAUCUS, NJ, 07094
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Timeliness |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-28 | M · Form 4[F1] | 22,677 | A | 112.17 | 60,234 | D | |
| Common Stock | 2026-08-28 | S · Form 4[F1] | 16,010 | D | 242.8755[F2] | 44,224 | D | |
| Common Stock | 2026-08-28 | S · Form 4[F1] | 6,237 | D | 243.6275[F3] | 37,987 | D | |
| Common Stock | 2026-08-28 | S · Form 4[F1] | 430 | D | 244.5148[F4] | 37,557 | D | |
| Common Stock | 2026-08-28 | G · Form 5[F5] | 1,000 | D | 0 | 36,557 | D | E |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
- G · Form 5
- Bona fide gift
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 5,780[F6] | I | 401(k)/SDCP |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualifed Stock Option (right to buy) | 112.17 | 2026-08-28 | M · Form 4[F1] | 22,677 | D | 112.17 | [F7] | 2030-02-18 | Common Stock | 22,677 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.↩ 1↩ 2↩ 3↩ 4↩ 5
- F2
- This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F3
- This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F4
- This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.↩ 1
- F5
- On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4.↩ 1
- F6
- These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.↩ 1
- F7
- The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.↩ 1
Signature 1
- Signed
- Sean D. Mersten, Attorney in Fact for Michael E. Prevoznik
- Date
- 2026-08-31
Company context
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www. QuestDiagnostics.com.
Current securities
Recent company filings
- SCHEDULE 13G - filed by STATE STREET CORP regarding QUEST DIAGNOSTICS INCNov 10, 2026
- 10-Q filingOct 23, 2026
- Other EventsOct 22, 2026
- Results of Operations and Financial ConditionOct 22, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 6, 2026